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incidence of Guiliain-Barre syndrome and recent developments in its prognosis, we analysed the severity and prognosis of Guillain-Barre syndrome in children diagnosed and treated during the years 1980-6 throughout Finland. The criteria for GuillainBarre syndrome were fulfilled in 14 boys and 13 girls. The mean annual number of cases of Guillain-Barre4 syndrome was thus 3-9, giving a mean annual incidence of 0-38/100 000 of population under 15 years of age (95% confidence intervals 0.25 to 0-56/100 000). The incidence of Guillain-Barre syndrome causing permanent neurological defects in children under 15 years of age was 1-4/10 million annually (95% confidence intervals 0*035 to 7-8/10 million). Our figures appeared to be one fourth to a half of that reported earlier in children and even lower than those in adults. Although there were no deaths among our patients, mortality from Guillain-Barre syndrome seems to have remained similar for the last 20 years despite current awareness of the possibility of cardiac arrest and respiratory failure.
Patients and methods

SOURCES OF DATA
The Finnish National Board of Health keeps a central database on the diagnosis, sex, and age of the patients discharged from all the hospitals in the country. Patients discharged during the period from 1 January 1980 to 31 December 1986 from paediatric wards with a diagnosis of any kind of polyneuropathy were listed and their case histories reviewed by us. The mean population at risk in Finland during 1980-6 was 1-02 million.
CRITERIA FOR GUILLAIN-BARRE SYNDROME The findings listed by the Guillain-Barre' syndrome study group were used as criteria (table   1) .9 The case histories of 83 children were reviewed by a paediatric neurologist (HR) and 14 boys and 13 girls were found to fulfil the criteria.
STATISTICAL METHODS
The occurrence of cases of Guillain-Barre syndrome was assumed to follow an even distribution in time and place. Confidence intervals were calculated based on a Poisson distribution.
The overall annual incidence of the GuillainBarre syndrome has been estimated to be 1-7/ 100 000 persons, In order to obtain more information about the incidence of Guillain-Barre syndrome and recent developments in its prognosis, we analysed its severity and prognosis in children, reviewing the literature and the records of patients diagnosed and treated during the years 1980-6 over the whole of Finland.
Results
The mean annual number of cases of GuillainBarre syndrome was 3 9, giving a mean annual incidence of 0-38/100 000 of population under 15 years of age (95% confidence intervals 0-25 to 0-56/100 000). The incidence of Guillain-Barre syndrome causing permanent neurological defects in children under 15 years of age was 1-4/10 million annually (95% confidence intervals 0 035 to 7-8/10 million). The patients were evenly distributed in terms of age, which varied between 0-4 and 14-3 years. A preceding infection was verified in 23 patients with respiratory symptoms occurring most frequently (n= 18). A vaccination before the symptoms was recorded in 11 patients.
The disease began from the lower extremities in 25 patients, one had paresis of the urinary bladder as the first sign of the disease, and one had paraesthesia (table 1) . Nine had facial palsy, three had paresis of the abducens nerve, one had a bilateral hypoglossus paresis, and two had bulbar paresis. Twenty children had pain in the back or in the lower extremities two to 14 days before the onset of the neurological defects. Four children had meningism. An increase in blood pressure requiring medical treatment was found in one patient. Occurrence, clinical manifestations, and prognosis ofGuillain-Barre syndrome Eighteen children required physiotherapy for a period of three weeks to 22 months (mean 155 days) after discharge from hospital; All the children became symptomless in 22 days to 22 months (mean 158 days), except for one girl who still has a severe sensory neuropathy 5 5 years after the acute phase.
Discussion
The annual incidence of Guillain-Barre syndrome in children under 15 years of age 0 38/ 100 000 is very low compared with that in adults. Kennedy et al found a lower incidence of Guillain-Barre syndrome among patients less than 40 years of age than in older ones, the incidence rates being 1 1 and 3-3/100 000 of population, respectively.1 They did not give any separate incidence figures for children, however. Our figures are one fourth or a half of those reported in Western Australia, which were 1-13/100 000 in children of 0-9 years of age and of 0-62/100 000 in patients of [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] years of age.'0 The figures are not fully comparable, however, as the numbers of children under 15 years of age are not available from their data.'0 Our study covered the whole population for seven years, during which there was a cluster of Guillain-Barre syndrome temporally associated with an oral polio vaccine campaign. " l Thus our figures, if anything, are somewhat higher than the real incidence. The cases were collected starting with a loose initial diagnosis to ensure that all cases were found. The heads of the paediatric wards in the country were aware that we were collecting cases of Guillain-Barre syndrome during 1980 to 1986 and this improved our coverage. Thus it is very unlikely that any significant number of cases were left unrecorded. Sometimes Guillain-Barre syndrome is difficult to diagnose, however, and those with a totally wrong diagnosis or a mild clinical symptomatology with myalgia and temporal muscular weakness could have been left out of our survey.
Although the acute symptoms were severe in most cases, the outcome was good. The The five children with the most severe symptoms in our survey needed assisted ventilation and received corticosteroids, and plasmapheresis was also performed on three of them. All returned to full health without any sequelae. The prognosis cannot be predicted on the basis of the severity of the acute phase.8 There is no evidence of corticosteroids being effective. 2 In the controlled trials of plasmapheresis in adults it has been found to be either ineffective or to have shortened the duration of severe weakness and assisted ventilation, but no effect has been reported on the mortality.9 13 14 The experience of plasmapheresis in Guillain-Barre syndrome in children is limited. Khatri et al reported good clinical responses in their uncontrolled series of 11 children with Guillain-Barre syndrome.'5 If plasmapheresis is to be used it should be employed in the early phase of the disease and by those who have experience with intensive plasmapheresis in paediatric patients. 5 Recently it has been reported that intravenously administered immune serum globulin may be beneficial in childhood Guillain-Barre syndrome. 16 No temporal trend in the prognosis was found in the combined data on Guillain-Barre Rantala, Uhari, Niemela The differential diagnosis of subacute polyneuropathy includes glue sniffing, diphtheria, botulism, heavy metal poisoning, poliomyelitis, organophosphate poisoning, myasthenia gravis (tick paralysis), and rabies.
The series of Rantala et al is similar to others in reporting the need for assisted ventilation
